Literature DB >> 28190209

Post-operative diffusion weighted imaging as a predictor of posterior fossa syndrome permanence in paediatric medulloblastoma.

Felicia H Z Chua1, Ady Thien2, Lee Ping Ng1, Wan Tew Seow1,2,3, David C Y Low1,2,3, Kenneth T E Chang4, Derrick W Q Lian4, Eva Loh4, Sharon Y Y Low5,6,7.   

Abstract

PURPOSE: Posterior fossa syndrome (PFS) is a serious complication faced by neurosurgeons and their patients, especially in paediatric medulloblastoma patients. The uncertain aetiology of PFS, myriad of cited risk factors and therapeutic challenges make this phenomenon an elusive entity. The primary objective of this study was to identify associative factors related to the development of PFS in medulloblastoma patient post-tumour resection.
METHODS: This is a retrospective study based at a single institution. Patient data and all related information were collected from the hospital records, in accordance to a list of possible risk factors associated with PFS. These included pre-operative tumour volume, hydrocephalus, age, gender, extent of resection, metastasis, ventriculoperitoneal shunt insertion, post-operative meningitis and radiological changes in MRI. Additional variables included molecular and histological subtypes of each patient's medulloblastoma tumour. Statistical analysis was employed to determine evidence of each variable's significance in PFS permanence.
RESULTS: A total of 19 patients with appropriately complete data was identified. Initial univariate analysis did not show any statistical significance. However, multivariate analysis for MRI-specific changes reported bilateral DWI restricted diffusion changes involving both right and left sides of the surgical cavity was of statistical significance for PFS permanence.
CONCLUSION: The authors performed a clinical study that evaluated possible risk factors for permanent PFS in paediatric medulloblastoma patients. Analysis of collated results found that post-operative DWI restriction in bilateral regions within the surgical cavity demonstrated statistical significance as a predictor of PFS permanence-a novel finding in the current literature.

Entities:  

Keywords:  Cerebellar mutism; Medulloblastoma; Posterior fossa syndrome

Mesh:

Year:  2017        PMID: 28190209     DOI: 10.1007/s00381-017-3356-7

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  48 in total

Review 1.  Local control of gliomas: the next best step--a good step?

Authors:  M Westphal; A Giese
Journal:  Front Radiat Ther Oncol       Date:  1999

Review 2.  Cerebellar mutism: report of two unusual cases and review of the literature.

Authors:  Y Erşahin; S Mutluer; S Saydam; E Barçin
Journal:  Clin Neurol Neurosurg       Date:  1997-05       Impact factor: 1.876

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

Review 4.  Mutism after posterior fossa surgery. Review of the literature.

Authors:  M Gelabert-González; J Fernández-Villa
Journal:  Clin Neurol Neurosurg       Date:  2001-07       Impact factor: 1.876

5.  Neuropsychological sequelae of the treatment of children with medulloblastoma.

Authors:  M Dennis; B J Spiegler; C R Hetherington; M L Greenberg
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

Review 6.  The cerebellar mutism syndrome and its relation to cerebellar cognitive function and the cerebellar cognitive affective disorder.

Authors:  Elizabeth M Wells; Karin S Walsh; Zarir P Khademian; Robert F Keating; Roger J Packer
Journal:  Dev Disabil Res Rev       Date:  2008

Review 7.  The pathophysiology of oral pharyngeal apraxia and mutism following posterior fossa tumor resection in children.

Authors:  A T Dailey; G M McKhann; M S Berger
Journal:  J Neurosurg       Date:  1995-09       Impact factor: 5.115

8.  Diffusion-weighted magnetic resonance imaging of acute focal cerebral ischemia: comparison of signal intensity with changes in brain water and Na+,K(+)-ATPase activity.

Authors:  J Mintorovitch; G Y Yang; H Shimizu; J Kucharczyk; P H Chan; P R Weinstein
Journal:  J Cereb Blood Flow Metab       Date:  1994-03       Impact factor: 6.200

9.  Clinical and neuroanatomical predictors of cerebellar mutism syndrome.

Authors:  Nicole Law; Mark Greenberg; Eric Bouffet; Michael D Taylor; Suzanne Laughlin; Douglas Strother; Christopher Fryer; Dina McConnell; Juliette Hukin; Caelyn Kaise; Frank Wang; Donald J Mabbott
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

10.  Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples.

Authors:  Paul A Northcott; David J H Shih; Marc Remke; Yoon-Jae Cho; Marcel Kool; Cynthia Hawkins; Charles G Eberhart; Adrian Dubuc; Toumy Guettouche; Yoslayma Cardentey; Eric Bouffet; Scott L Pomeroy; Marco Marra; David Malkin; James T Rutka; Andrey Korshunov; Stefan Pfister; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2011-11-06       Impact factor: 17.088

View more
  3 in total

1.  Establishing reproducible predictors of cerebellar mutism syndrome based on pre-operative imaging.

Authors:  Heng Zhang; Zhiyi Liao; Xiaolei Hao; Zhe Han; Chunde Li; Jian Gong; Wei Liu; Yongji Tian
Journal:  Childs Nerv Syst       Date:  2019-02-06       Impact factor: 1.475

2.  Basilar Artery Vasospasm as a Cause of Post-Operative Cerebellar Mutism Syndrome.

Authors:  Marwa Deghedy; Barry Pizer; Ram Kumar; Conor Mallucci; Shivaram Avula
Journal:  Case Rep Pediatr       Date:  2022-02-10

3.  Cerebrospinal fluid cytokines in metastatic group 3 and 4 medulloblastoma.

Authors:  Sharon Y Y Low; Nurfahanah Bte Syed Sulaiman; Enrica E K Tan; Lee Ping Ng; Chik Hong Kuick; Kenneth T E Chang; Phua Hwee Tang; Ru Xin Wong; Wen Shen Looi; David C Y Low; Wan Tew Seow
Journal:  BMC Cancer       Date:  2020-06-15       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.